Moleculin Reports Positive Interim MIRACLE Trial Data in Venetoclax-Failed AML Patients
HOUSTON, July 31, 2026 Moleculin Biotech, Inc. announced updated positive preliminary blinded interim results from Part A of its...
relapsed AML
Advertisement
Cullinan Therapeutics Plans Registrational Phase 2 Trial for CLN-049
CAMBRIDGE, Mass., July 28, 2026 Cullinan Therapeutics announced positive feedback from the U.S. Food and Drug Administration (FDA) following...
Moleculin Reports Positive MIRACLE Trial Results
HOUSTON, July 6, 2026 Moleculin Biotech announced that Chairman and Chief Executive Officer Walter Klemp discussed encouraging preliminary results...
AvenCell Therapeutics to Present First Phase 1 Results for Switchable Allogeneic CAR-T Therapy in AML
WATERTOWN, Massachusetts, USA & DRESDEN, Germany, June 2, 2026 AvenCell Therapeutics has announced that it will present results from...
Advertisement
